Zylox-Tonbridge Revenue Climbs as International Sales Surge

Net profit for the six-month period ending June 30 climbed 47.8% to RMB 179 million, with profit margins reaching 28.3%. This financial performance coincides with the strategic integration of optimed, the German medical technology firm in which Zylox-Tonbridge acquired a 60% stake in April. The move has allowed the company to unify sales teams across Europe and establish direct sales networks in Germany, France, and Austria, reaching over 80% of group purchasing organizations in those key markets.

While the international division now accounts for 11.2% of total revenue, the domestic sector remains a steady anchor. The company secured NMPA approval for 11 new products in China during the first half of the year, bolstering its neurovascular and peripheral vascular portfolios. Products such as the Kylin Flow Diverter and SilverSnake catheter series continue to drive domestic volume, while the company maintains its innovation pipeline with 10 devices currently in the NMPA’s Special Review Procedure. Looking ahead, the firm plans to leverage its combined supply-chain and precision-engineering capabilities to sustain growth across its distribution network, which now spans more than 135 countries.